VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to evaluate safety and effectiveness of the treatment of multiple myeloma with bortezomib in daily practice in the Netherlands.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen-Cilag B.V.
• Treatments: Bortezomib

Criteria

Inclusion Criteria:

• Patients have to sign a statement that they agree with collection of their clinical data for this project

• the patient is eligible, in the investigator's opinion, based on the criteria in the summary of product characteristics for bortezomib

Exclusion Criteria:

• If patients meet the eligibility criteria, there are no exclusion criteria.